(WRB) W. R. Berkley - Overview
Stock: Commercial Insurance, Reinsurance, Excess Lines, Specialty Products
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.63% |
| Yield on Cost 5y | 7.09% |
| Yield CAGR 5y | -2.05% |
| Payout Consistency | 93.7% |
| Payout Ratio | 43.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 21.7% |
| Relative Tail Risk | -3.05% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.64 |
| Alpha | 12.26 |
| Character TTM | |
|---|---|
| Beta | 0.211 |
| Beta Downside | 0.159 |
| Drawdowns 3y | |
|---|---|
| Max DD | 18.54% |
| CAGR/Max DD | 1.01 |
Description: WRB W. R. Berkley December 17, 2025
W. R. Berkley Corp. (NYSE:WRB) is a global commercial-line insurer organized into two operating segments: Insurance, which underwrites a broad mix of admitted and excess-surplus lines-including casualty, property, specialty, cyber, and personal-lines products-and Reinsurance & Monoline Excess, which provides treaty and facultative reinsurance solutions across property-casualty and niche turnkey coverages.
Key metrics as of the latest filing (Q3 2024) show net written premiums of $7.2 billion, a combined ratio of 93.5 % (indicating underwriting profitability), and a return on equity (ROE) of 12.8 %-both above the industry median of roughly 90 % combined ratio and 10 % ROE. The segment’s performance is sensitive to macro-economic drivers such as U.S. commercial construction activity, corporate litigation trends, and the frequency of cyber events, which have been rising at an estimated 8 % CAGR over the past five years.
For a deeper dive into WRB’s valuation assumptions and how its risk-adjusted return compares to peers, you may find it useful to explore the analytics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 1.78b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -0.98 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA 0.08 > 3% & CFO 3.40b > Net Income 1.78b |
| Net Debt (2.84b) to EBITDA (2.37b): 1.20 < 3 |
| Current Ratio: error (cannot be calculated; needs correct Total Current Assets and Liabilities) |
| Outstanding Shares: last quarter (399.1m) vs 12m ago -0.44% < -2% |
| Gross Margin: 19.81% > 18% (prev 0.23%; Δ 1958 % > 0.5%) |
| Asset Turnover: 34.75% > 50% (prev 33.62%; Δ 1.13% > 0%) |
| Interest Coverage Ratio: 14.22 > 6 (EBITDA TTM 2.37b / Interest Expense TTM 126.9m) |
What is the price of WRB shares?
Over the past week, the price has changed by +2.67%, over one month by +0.60%, over three months by -4.08% and over the past year by +17.59%.
Is WRB a buy, sell or hold?
- StrongBuy: 5
- Buy: 1
- Hold: 8
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the WRB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 68.3 | -3% |
| Analysts Target Price | 68.3 | -3% |
| ValueRay Target Price | 80.3 | 14% |
WRB Fundamental Data Overview February 07, 2026
P/E Forward = 15.015
P/S = 1.8193
P/B = 2.7289
P/EG = 10.7311
Revenue TTM = 14.71b USD
EBIT TTM = 1.80b USD
EBITDA TTM = 2.37b USD
Long Term Debt = 2.84b USD (from longTermDebt, two quarters ago)
Short Term Debt = 12.5m USD (from shortTermDebt, two quarters ago)
Debt = 2.84b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 2.84b USD (using Total Debt 2.84b, CCE unavailable)
Enterprise Value = 29.60b USD (26.76b + Debt 2.84b - (null CCE))
Interest Coverage Ratio = 14.22 (Ebit TTM 1.80b / Interest Expense TTM 126.9m)
EV/FCF = 8.89x (Enterprise Value 29.60b / FCF TTM 3.33b)
FCF Yield = 11.25% (FCF TTM 3.33b / Enterprise Value 29.60b)
FCF Margin = 22.64% (FCF TTM 3.33b / Revenue TTM 14.71b)
Net Margin = 12.10% (Net Income TTM 1.78b / Revenue TTM 14.71b)
Gross Margin = 19.81% ((Revenue TTM 14.71b - Cost of Revenue TTM 11.79b) / Revenue TTM)
Gross Margin QoQ = 20.58% (prev 18.23%)
Tobins Q-Ratio = 0.67 (Enterprise Value 29.60b / Total Assets 44.07b)
Interest Expense / Debt = 1.11% (Interest Expense 31.6m / Debt 2.84b)
Taxrate = 20.49% (117.2m / 572.0m)
NOPAT = 1.43b (EBIT 1.80b * (1 - 20.49%))
Current Ratio = unknown (Total Current Assets 2.73b / Total Current Liabilities none)
Debt / Equity = 0.29 (Debt 2.84b / totalStockholderEquity, two quarters ago 9.80b)
Debt / EBITDA = 1.20 (Net Debt 2.84b / EBITDA 2.37b)
Debt / FCF = 0.85 (Net Debt 2.84b / FCF TTM 3.33b)
Total Stockholder Equity = 9.10b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.20% (Net Income 1.78b / Total Assets 44.07b)
RoE = 19.55% (Net Income TTM 1.78b / Total Stockholder Equity 9.10b)
RoCE = 15.11% (EBIT 1.80b / Capital Employed (Equity 9.10b + L.T.Debt 2.84b))
RoIC = 11.78% (NOPAT 1.43b / Invested Capital 12.18b)
WACC = 6.13% (E(26.76b)/V(29.60b) * Re(6.69%) + D(2.84b)/V(29.60b) * Rd(1.11%) * (1-Tc(0.20)))
Discount Rate = 6.69% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.91%
[DCF Debug] Terminal Value 86.62% ; FCFF base≈3.38b ; Y1≈3.85b ; Y5≈5.26b
Fair Price DCF = 373.0 (EV 143.51b - Net Debt 2.84b = Equity 140.67b / Shares 377.2m; r=6.13% [WACC]; 5y FCF grow 15.94% → 2.90% )
EPS Correlation: -8.08 | EPS CAGR: 0.72% | SUE: -0.14 | # QB: 0
Revenue Correlation: 94.48 | Revenue CAGR: 6.71% | SUE: 3.11 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.16 | Chg30d=-0.004 | Revisions Net=-6 | Analysts=15
EPS current Year (2026-12-31): EPS=4.58 | Chg30d=-0.057 | Revisions Net=-10 | Growth EPS=+5.7% | Growth Revenue=+4.7%
EPS next Year (2027-12-31): EPS=4.84 | Chg30d=-0.124 | Revisions Net=-8 | Growth EPS=+5.8% | Growth Revenue=+4.7%